45
Participants
Start Date
January 12, 2017
Primary Completion Date
August 22, 2019
Study Completion Date
August 22, 2019
Dapagliflozin
Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
Glimepiride
Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
University of Michigan, Ann Arbor
Collaborators (1)
AstraZeneca
INDUSTRY
University of Michigan
OTHER